Inferra AI / Company / KARD
Kardigan, Inc.
KARD · Health Care
Last earnings Aug 11, 2026
AI analysis
Q2 2026 · reported Aug 11, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
The Company may seek to raise additional capital in the future through equity or debt financings, license agreements, or other sources of financing, although there can be no assurance that such financing will be available on terms acceptable to the Company, or at all.
Significant estimates and assumptions include, but are not limited to: the fair value of common stock prior to the Company's initial public offering, the fair value of common stock warrants, the fair value of preferred stoc k tranche obligations, purchase price allocations for acquisitions, the fair value of contingent milestone liabilities, the valuation of stock-based awards, the assessment of useful life and recoverability of long-lived assets, the estimated incremental borrowing rate used in operating lease calculations, the accrual of research and development costs, and the valuation allowance for deferred tax assets.
Event summary
Kardigan, Inc. — Earnings release (2026-08-11)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The Company may seek to raise additional capital in the future through equity or debt financings, license agreements, or other sources of financing, although there can be no assurance that such financing will be available on terms acceptable to the Company, or at all.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Significant estimates and assumptions include, but are not limited to: the fair value of common stock prior to the Company's initial public offering, the fair value of common stock warrants, the fair value of preferred stoc k tranche obligations, purchase price allocations for acquisitions, the fair value of contingent milestone liabilities, the valuation of stock-based awards, the assessment of useful life and recoverability of long-lived assets, the estimated incremental borrowing rate used in operating lease calculations, the accrual of research and development costs, and the valuation allowance for deferred tax assets.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Investments The Company s investments consist of marketable debt securities.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Marketable debt securities with contractual maturities of less than 12 months at the balance sheet date are considered short-term marketable securities.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Marketable debt securities with contractual maturities of 12 months or greater at the balance sheet date are considered long-term marketable 10 securities.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The amortized cost of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Strategy & priorities
Our forward-looking statements include, but are not limited to, statements regarding our or our management team s expectations, hopes, beliefs, intentions or strategies regarding the future.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Operating segments The Company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The extent of the impact of these factors on the Company s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected timeframe, will depend on future developments, which are uncertain and cannot be 9 predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company s business.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Factors that could affect the Company s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company s potential drug candidates, uncertainty of market acceptance of any of the Company s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and market competition, securing and protecting proprietary technology, the ability to obtain and maintain intellectual property protection, strategic relationships and dependence on key individuals and vendors.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Risks & headwinds
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Kardigan’s business, operating results, financial condition and stock value.
SEC original ↗Kardigan, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026
Legal Proceedings 57 Item 1A.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
These forward-looking statements are based on information available to us at the time of this Quarterly Report and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
1 SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous risks and uncertainties, which include, but are not limited to, the following: We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability.
SEC original ↗Kardigan, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
4 documentsEarnings releases
2 documentsPresentations
0 documentsNo presentations for Kardigan, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Kardigan, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.